Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The attitudes of pregnant women and midwives towards raised BMI in a maternity setting: A discussion of two repertory grid studies.

Hodgkinson EL, Smith DM, Hare DJ, Wittkowski A.

Midwifery. 2017 Feb;45:14-20. doi: 10.1016/j.midw.2016.12.004. Epub 2016 Dec 6.

PMID:
27960121
2.

The Construal of Midwives by Pregnant Women with a Body Mass Index Greater Than or Equal to 30 kg/m2 (BMI ≥ 30 kg/m2 ): A Repertory Grid Study.

Hodgkinson EL, Smith DM, Hare DJ, Wittkowski A.

Clin Psychol Psychother. 2017 Mar;24(2):392-400. doi: 10.1002/cpp.2009. Epub 2016 Mar 3.

PMID:
26936253
3.

Using the Repertory Grid Technique to Examine Trainee Clinical Psychologists' Construal of Their Personal and Professional Development.

Hill K, Wittkowski A, Hodgkinson E, Bell R, Hare DJ.

Clin Psychol Psychother. 2016 Sep;23(5):425-437. doi: 10.1002/cpp.1961.

PMID:
25963799
4.

Optimisation of pharmacy content in clinical cancer research protocols: Experience of the United Kingdom Chemotherapy and Pharmacy Advisory Service.

Debruyne PR, Johnson PJ, Pottel L, Daniels S, Greer R, Hodgkinson E, Kelly S, Lycke M, Samol J, Mason J, Kimber D, Loucaides E, Parmar MK, Harvey S; NIHR CRN – CPAS.

Clin Trials. 2015 Jun;12(3):257-64. doi: 10.1177/1740774515569610. Epub 2015 Feb 4.

PMID:
25652529
5.

Women's experiences of their pregnancy and postpartum body image: a systematic review and meta-synthesis.

Hodgkinson EL, Smith DM, Wittkowski A.

BMC Pregnancy Childbirth. 2014 Sep 23;14:330. doi: 10.1186/1471-2393-14-330. Review.

6.

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, Wilson RH, Jasani B, Taylor GR, Williams GT, Sampson JR, Seymour MT, Nichols LL, Kenny SL, Nelson A, Sampson CM, Hodgkinson E, Bridgewater JA, Furniss DL, Roy R, Pope MJ, Pope JK, Parmar M, Quirke P, Kaplan R.

Br J Cancer. 2014 Apr 29;110(9):2178-86. doi: 10.1038/bjc.2014.182. Epub 2014 Apr 17.

7.

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium, Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group, Smith CG, West H, Cheadle JP; COIN Collaborative Group, Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.

Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.

8.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators.

Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.

9.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.

10.

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group.

Lancet. 2008 May 17;371(9625):1685-94. doi: 10.1016/S0140-6736(08)60727-8.

11.

Magnesium depletion in patients receiving cisplatin-based chemotherapy.

Hodgkinson E, Neville-Webbe HL, Coleman RE.

Clin Oncol (R Coll Radiol). 2006 Nov;18(9):710-8.

PMID:
17100159
12.
13.

Potential and pitfalls in establishing the provenance of Earth-related samples in forensic investigations.

Rawlins BG, Kemp SJ, Hodgkinson EH, Riding JB, Vane CH, Poulton C, Freeborough K.

J Forensic Sci. 2006 Jul;51(4):832-45.

PMID:
16882228
14.

A study of New Zealand wood workers: exposure to wood dust, respiratory symptoms, and suspected cases of occupational asthma.

Norrish AE, Beasley R, Hodgkinson EJ, Pearce N.

N Z Med J. 1992 May 27;105(934):185-7.

PMID:
1625823
15.

The Salmon Teaching Division. An RHB pilot (Regional Hospital Board).

Hodgkinson E.

Nurs Times. 1969 Feb 27;65(9):274-6. No abstract available.

PMID:
5766404

Supplemental Content

Loading ...
Support Center